Suppressive effect of secretory phospholipase A2 inhibitory peptide on interleukin-1beta-induced matrix metalloproteinase production in rheumatoid synovial fibroblasts, and its antiarthritic activity in hTNFtg mice.

Secretory phospholipase A2 (sPLA2) and matrix metalloproteinase (MMP) inhibitors are potent modulators of inflammation with therapeutic potential, but have limited efficacy in rheumatoid arthritis (RA). The objective of this study was to understand the inhibitory mechanism of phospholipase inhibitor from python (PIP)-18 peptide in cultured synovial fibroblasts (SF), and to evaluate its therapeutic potential in a human tumor necrosis factor (hTNF)-driven transgenic mouse (Tg197) model of arthritis.
Gene and protein expression of sPLA2-IIA, MMP-1, MMP-2, MMP-3, MMP-9, tissue inhibitor of metalloproteinase (TIMP)-1, and TIMP-2 were analyzed by real time PCR and ELISA respectively, in interleukin (IL)-1beta stimulated rheumatoid arthritis (RA) and osteoarthritis (OA) synovial fibroblasts cells treated with or without inhibitors of sPLA2 (PIP-18, LY315920) or MMPs (MMP Inhibitor II). Phosphorylation status of mitogen-activated protein kinase (MAPK) proteins was examined by cell-based ELISA. The effect of PIP-18 was compared with that of celecoxib, methotrexate, infliximab and antiflamin-2 in Tg197 mice after ip administration (thrice weekly for 5 weeks) at two doses (10, 30 mg/kg), and histologic analysis of ankle joints. Serum sPLA2 and cytokines (tumor necrosis factor (TNF)alpha, IL-6) were measured by Escherichia coli (E coli) assay and ELISA, respectively.
PIP-18 inhibited sPLA2-IIA production and enzymatic activity, and suppressed production of MMPs in IL-1beta-induced RA and OA SF cells. Treatment with PIP-18 blocked IL-1beta-induced p38 MAPK phosphorylation and resulted in attenuation of sPLA2-IIA and MMP mRNA transcription in RA SF cells. The disease modifying effect of PIP-18 was evidenced by significant abrogation of synovitis, cartilage degradation and bone erosion in hTNF Tg197 mice.
Our results demonstrate the benefit that can be gained from using sPLA2 inhibitory peptide for RA treatment, and validate PIP-18 as a potential therapeutic in a clinically relevant animal model of human arthritis.
AuthorsMaung-Maung Thwin, Eleni Douni, Pachiappan Arjunan, George Kollias, Prem V Kumar, Ponnampalam Gopalakrishnakone
JournalArthritis research & therapy (Arthritis Res Ther) Vol. 11 Issue 5 Pg. R138 ( 2009) ISSN: 1478-6362 [Electronic] England
PMID19765281 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • Enzyme Inhibitors
  • Interleukin-1beta
  • Peptides
  • Tumor Necrosis Factor-alpha
  • Phospholipases A2, Secretory
  • Matrix Metalloproteinases
  • Animals
  • Arthritis, Rheumatoid (drug therapy, metabolism)
  • Enzyme Inhibitors (pharmacology)
  • Enzyme-Linked Immunosorbent Assay
  • Fibroblasts (drug effects, metabolism)
  • Gene Expression
  • Humans
  • Interleukin-1beta (metabolism)
  • Matrix Metalloproteinases (biosynthesis, drug effects)
  • Mice
  • Mice, Transgenic
  • Peptides (pharmacology)
  • Phospholipases A2, Secretory (antagonists & inhibitors)
  • Reverse Transcriptase Polymerase Chain Reaction
  • Synovial Membrane (cytology, drug effects, metabolism)
  • Transcription, Genetic
  • Tumor Necrosis Factor-alpha (genetics)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!

Choose Username:
Verify Password: